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Abstract
Background: Inflammatory bowel disease constitutes a heterogeneous group of conditions, whose aetiology is
only partly understood. The prevailing hypothesis on its pathogenesis is that IBD is the result of an inadequate
immune response to the resident bacterial flora of the intestine. An autoimmune background, however, has been
discussed since the 1950s. Lately, it has been shown that failures in interleukin-10 (IL-10) signalling due to IL-10-
and IL-10 receptor (IL-10R) mutations result in IBD. Our study aimed at investigating the existence of inhibitory
autoantibodies against IL-10 and IL-10R in IBD patients capable of down-modulating IL-10 signalling thereby
mimicking IL-10 or IL-10R deficiency.
Results: Thirteen IBD patients had IgG autoantibodies against IL-10, IL-10RA and/or IL-10RB, and three patients had IgA
autoantibodies against IL-10. However, the absolute OD values of the serum antibodies measured by ELISA were low,
there was overall no significant difference between patients and controls, and positive sera had no neutralizing activity.
Conclusion: No evidence for an involvement of autoantibodies against IL-10 or IL-10R in the pathogenesis of
inflammatory bowel disease could be established.
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Background
Inflammatory bowel disease (IBD) includes Crohn’s dis-
ease, ulcerative colitis and indeterminate colitis and is
characterized by a chronic and relapsing inflammation
of the small or large intestine, abdominal pain, diarrhea,
bleeding and malabsorption. With a prevalence of up to
450 per 100,000 inhabitants in the UK, IBD constitutes a
common inflammatory condition; hence, the impact of
associated morbidity and mortality is estimated to be
substantial [1].
IBD is considered as the result of an excessive and in-
adequate immune response to commensals of the intes-
tine, defining IBD as a pro-inflammatory disorder [2]. In
addition, at least in a subgroup of patients, IBD might also
be an immunodeficiency due to impaired release of pro-
inflammatory cytokines by macrophages [3,4]. This hy-
pothesis is supported by several primary immunodeficien-
cies that are characterized by IBD-like phenotypes such as
IPEX syndrome, XIAP deficiency, and NEMO deficiency
[5-7]. IL-10- and IL-10R deficiencies add to these disor-
ders: affected patients manifest with severe early-onset en-
terocolitis which shows a dramatic and life-threatening
progress [8-10]. The latter underscore the necessity of IL-
10 to control inflammation and keep our immune system
in balance [11-13].
For a long time, an autoimmune background has been
suggested for IBD, and antibodies against numerous
auto-antigens have been detected [14-18]. In 2009, Ebert
et al. described autoantibodies against various cytokines
in IBD patients leading to a state of relative deficiency of
IL2, TGF-β and IL-10 [19]. Given the relevance of IL-10
as the key immunomodulatory factor of the human im-
mune system, neutralizing autoantibodies against IL-10
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or IL-10R might significantly impair IL-10 signalling and
contribute to the severity of IBD.
In this study, we aimed to investigate the existence of
autoantibodies binding to IL-10 or to the IL-10R, thus
abrogating IL-10 signalling and mimicking a state of IL-10
deficiency. Here, we present the results of a screening for
autoantibodies of the IgG and IgA isotype, putatively
directed against IL-10 signalling components in 52 IBD
patients.
Results and discussion
Antibodies against IL-10
Antibodies of the IgG isotype
Sera of 20 healthy donors as well as 52 IBD patients
were subjected to ELISA testing in search of anti-IL-
10 IgG antibodies. Upon testing, eight out of 52 IBD
patients (15%) showed OD values above a cut-off of
μ + 3SD (Figure 1A). Data were analyzed by t-test,
comparing the Crohn’s disease (CD) and ulcerative
colitis (UC) groups both to the healthy control group.
We found the CD group to exhibit significantly ele-
vated levels of anti-IL-10 IgG antibodies, whereas the
UC group testing resulted in a non-significant p-value
(p = 0.41). In our cohort, 18% of CD patients (7/38)
had anti-IL-10 autoantibodies; this replicates the re-
sults of Ebert et al. [19], who found 17% of CD pa-
tients to have anti-IL-10 IgG autoantibodies in the
serum, thus validating our results in spite of a small
sample size.
However, it has also been reported that anti-IL-10 anti-
bodies may be present in high titers in healthy blood do-
nors [20,21], and anti-cytokine autoantibodies are believed
to occur ubiquitously in healthy individuals [22]. Fur-
thermore, in contrast to other diseases with neutralizing
anti-cytokine autoantibodies [23,24], but similar to the
anti-IL-10 antibodies found by Ebert et al. [19], the in-
crease in OD values was not striking in our patients.
Antibodies of the IgA isotype
Previous studies only reported on IgG anti-IL-10 anti-
bodies in their populations. However, IgA constitutes a
crucial element of mucosal immunity and is the most
abundant immunoglobulin in the gut. Thus, its putative
role in IBD has often been speculated upon and early re-
ports implied that abnormal IgA function may play a
role in the pathogenesis of IBD [25].
We therefore extended our search for the detection of
anti-IL-10 autoantibodies of the IgA isotype. The sera of
52 IBD patients, i.e. 38 CD and 14 UC patients, and 10
randomly chosen healthy donors were probed.
In three patients (2 CD and 1 UC), elevated ODs were
found for anti-IL-10 IgA autoantibodies, while means of
all groups were not significantly different (Figure 1B).
The number of patients with anti-IL-10 IgA autoanti-
bodies might however, be underestimated with the chosen
assay. Probing of serum samples may not be the best
method to detect autoantibodies of the IgA isotype, as anti-
bodies may accumulate in the inflamed tissue of the gut so
that concentrations significantly higher than in the serum
may be reached. Also, while IgA makes up two thirds of
the produced antibodies, it is mostly secreted so that it
constitutes only 15% of the immunoglobulins present in
human serum. Additionally, it is possible that the titre of
autoantibodies fluctuates over time in a given patient.
In conclusion, our results suggest that single IBD pa-
tients might produce class IgA autoantibodies against
IL-10. Yet, the significance of these antibodies is unclear.
Antibodies against the IL-10R
Antibodies of the IgG isotype
In order to investigate whether IBD patients might pro-
duce IgG antibodies binding to the IL-10 receptor, sera
of 50 healthy blood donors and 52 IBD patients were
analysed by ELISA for binding to either recombinant IL-
10R1 or IL-10R2 (Figure 2A).
Figure 1 Autoantibodies against IL-10. Serum samples of patients suffering from inflammatory bowel disease were tested for anti-IL-10
Immunoglobulin G (A) and Immunoglobulin A (B) by ELISA. The dotted line represents the cut-off, whereas means are depicted as solid lines.
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Neither for anti-IL-10R1 nor for anti-IL-10R2 significant
differences between means of IBD patients and healthy
blood donors could be detected; statistical analysis failed
to reach the significance level of p < 0.05. Stratifying pa-
tients according to the site of disease manifestation did
not change the results (Additional file 1: Figure S1).
However, few patients proved to have significantly ele-
vated ODs of up to 4 times the mean suggesting that some
IBD patients do produce autoantibodies against IL-10R1
or IL-10R2. In the CD group, three out of 38 patients (8%)
tested for anti-IL-10R2 had values that were higher than
any value measured in the healthy donor group (method
after [19]), compared to one out of 14 patients (7%) in the
UC group. Regarding anti-IL-10R1, four out of 38 CD pa-
tients (11%) and one out of 14 UC patients (7%) had ele-
vated values.
Another method to determine a cut-off for positive
values is to calculate μ + 2SD or μ + 3SD, i.e. the mean of
a healthy donor population and addition of 2 or 3 stand-
ard deviations. Using the μ + 3SD method on our samples
provided exactly the same results as the method described
above, i.e. one UC and four CD patients were above the
calculated cut-off for anti-IL-10R1 and one UC and three
CD patients for anti-IL-10R2. Thus, IgG autoantibodies
against the IL-10R seem to be produced by a non-
significant number of patients in our cohort.
Antibodies of the IgA isotype
The sera of 52 IBD patients, i.e. 38 CD and 14 UC pa-
tients, and 10 randomly chosen healthy donors were
probed for anti-IL-10R autoantibodies of the IgA isotype.
No increased absorption values were found for anti-
IL-10R1 and anti-IL-10R2 IgA autoantibodies in pa-
tients’ sera (Figure 2B), indicating that neither Crohn’s
disease nor ulcerative colitis patients from our cohort
produce IgA autoantibodies against the IL-10R.
Limitations of the ELISA technology as a screening method
Recombinant proteins, such as the rIL-10R1 and rIL-
10R2, may have different epitopes than the in vivo recep-
tor on the cell surface. Hence, antibodies binding to the
rIL-10R might in fact not recognize the IL-10 receptor
in vivo and vice versa. Furthermore, it is well known that
surface-protein interactions, e.g. between the ELISA plate
and the recombinant protein, can induce conformational
changes and therefore subsequently inhibit or facilitate
A
B
Figure 2 Autoantibodies against the IL-10 receptor. Serum samples of IBD patients and healthy donors were tested by ELISA for IgG (A) and
IgA (B) antibodies binding to IL-10R1 and IL-10R2. The dotted line represents the cut-off, whereas means are depicted as solid lines.
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antibody binding. In order to address these limitations,
a functional assay was developed to evaluate the ELISA
results.
Functional test for neutralizing activity of anti-IL-10R
antibodies
To assess whether the detected IL-10R autoantibodies
have functional consequences, their impact on STAT3
phosphorylation, a key event in IL-10 signalling, was
determined.
Sera of UC and CD patients (n = 21) were compared
with serum of a healthy donor control. A commercial
antibody directed against IL-10R2 (R&D, UK) was used
as a positive control. Analysis of STAT3 phosphorylation
upon IL-10 stimulation of PBMCs pre-incubated with a
1:10 dilution of serum failed to demonstrate a significant
reduction of ODs, and therefore STAT3 phosphorylation,
in the IBD patient cohorts (Figure 3). There were no sig-
nificant differences between ELISA-positive and -negative
samples or between UC and CD samples.
In conclusion, we could not find evidence for the func-
tional relevance of autoantibodies against the IL-10 recep-
tor. Neither did we find any evidence for the existence of
autoantibodies, which were not detected by ELISA but
had a sufficiently high titer to significantly reduce down-
stream signalling.
Single and multiple positives
In total, 13 of 52 patients (25%) were found to have
autoantibodies against IL-10 or the IL-10R subunits IL-
10R1 and IL-10R2 (Table 1).
Whereas eight patients had antibodies against either
IL-10 or one subunit of the IL-10R alone, sera of four
patients were double positive for antibodies against IL-
10 and IL-10R; one patient had serum triple positive for
anti-IL-10, anti-IL-10R1 and anti-IL-10R2 antibodies.
The latter patients might generally have an increased
auto-immune status with possibly other autoantibodies
in the serum as well. This, the low absolute OD values,
and the fact that the IL-10R autoantibodies had no neu-
tralizing activity, suggest that the autoantibodies might
not be of overall significance.
Conclusion
Our results do not provide sufficient evidence to postu-
late a general autoimmune disruption of IL-10 signalling
in the pathogenesis of IBD.
Overall, no significant difference could be detected be-
tween IBD patients and healthy controls, with only single-
ton patients having been tested positive for autoantibodies
against IL-10 and/or IL-10R in serum. Furthermore, the
absolute OD values of detected autoantibodies were low
with only a minor increase above the cut-off level in most
positive patients. Most significantly, the sera positive for
anti-IL-10R antibodies failed to show neutralizing activity
in a functional test, further supporting the assumption
that the detected antibodies are of little significance.
Lastly, the finding that some patients were double or even
triple positive for autoantibodies against IL-10 and IL-10R
might reflect a low level autoimmune state with a broader
range of autoantibodies with unknown significance.
While the understanding of the molecular mechanisms
underlying inflammatory bowel disease gradually in-
creases, further research needs to be conducted in order
to identify the exact immune processes contributing to
the complex pathogenesis of IBD. Genetic and func-
tional data suggest IBD might be even more heteroge-
neous than initially expected [26,27]. Only after these
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Figure 3 Functional test assessing STAT3 phosphorylation.
PBMCs were incubated with healthy donor (HD) or patients’ sera
in a 1:10 dilution and subsequently stimulated with IL-10. Cells
were lysed and examined for STAT3 phosphorylation by ELISA. An
anti-IL10R2 antibody was used as a positive control. The OD of the
healthy donor control was set as 100%.
Table 1 Patients single or multiple positive for
antiautobodies against the IL-10 signalling pathway
No of patients
with antibodies
against:
IL-
10
IL-
10R1
IL-
10R2
IL-10 +
IL-10R1
IL-10 +
IL-10R2
IL-10 + IL-
10R1 + IL-10R2
IgG 3 2 1 1 2 1
IgA 2 - - 11 - -
Total no of
patients
5 2 1 2 2 1
1This patient had anti-IL-10 antibodies of the IgG and IgA isotype.
Thirteen patients had autoantibodies affecting the IL-10 signalling pathway.
Eight patients had antibodies against a single protein, and five patients had
antibodies against multiple components.
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topics have been addressed, more specific targeted ther-
apies can be developed.
Methods
Patient cohorts
Patients’ serum samples (n = 52) were collected from IBD
clinics in Freiburg and Paris, Necker Enfants Malades.
Thirty-eight patients had Crohn’s disease and 14 had ul-
cerative colitis. Patients were diagnosed according to the
Consensus of the European Crohn’s and Colitis Organisa-
tion (ECCO) [28,29] or the Porto-criteria and classified ac-
cording to the Paris classification [30,31]. Samples were
aliquoted upon receipt. All patients gave their informed
consent; approval was granted by the National Research
Ethics Service Committee London – Hampstead, formerly
North West London REC 2/ Royal Free Hospital and
Medical School REC, London, UK (Ref. 08/H0720/46 for
healthy donors and 04/Q0501/119 for patients).
Enzyme-linked immunosorbent assay (ELISA)
Flat-bottomed microtitre plates (Nunc-Immuno Plate
Maxisorp Surface) were coated with recombinant IL-
10R1 (R&D Systems) or IL-10R2 (Abnova) at a concen-
tration of 2 μg/ml or with 0.5 μg/ml IL-10 diluted in
carbonate buffer, pH 9.5 and incubated overnight at 4°C.
The plates were washed with PBS-Tween (0.05%). Free
binding sites on the plate were blocked with 300 μl 1% bo-
vine serum albumin (BSA) (Sigma, US) for an incubation
time of 1 h.
Human sera were added in a 1:200 dilution. Following a
2 h incubation period the plates were washed 5 times. The
secondary antibody was added and incubated for 1 h.
After washing, 100 μl of substrate TMB were added to
each well. Colour development was monitored and 50 μl
of 2 M sulphuric acid were added to stop the reaction. Ab-
sorption was determined in an ELISA reader at 450 nm.
STAT3 phosphorylation assay
Peripheral blood mononuclear cells (PBMCs) were isolated
using the Ficoll technique and then washed in PBS (Sigma,
US). 105 PBMCs were resuspended in 180 μL Opti-Mem I
serum-free medium (Invitrogen, UK), added in 96-well
plates and then pre-incubated for one hour with 20 μL
neat or 1:10 diluted serum from anti-IL-10R auto-antibody
positive patients. Cells were then stimulated with 5 ng IL-
10 (R&D, UK) for 10 minutes, lysed and examined for
STAT3 phosphorylation by ELISA (Cell signaling, UK) ac-
cording to manufacturer’s instructions.
Additional file
Additional file 1: Figure S1. Subgroup analysis of Crohn’s disease
patients from Paris. Crohn’s disease patients were subgrouped for disease
localisation after their sera were tested for IgG (A) and IgA (B)
autoantibodies against IL-10 and IgG autoantibodies against the IL-10
receptor (C) by ELISA. The dotted line represents the cut-off, whereas
means are depicted as solid lines.
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